In this study, we compared the first-line treatments of using pembrolizumab-pemetrexed-platinum combination versus bevacizumab-pemetrexed-platinum combination in advanced non-squamous NSCLC without sensitizing EGFR/ALK/ROS1 mutations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.